Aromatase and its inhibitors: significance for breast cancer therapy.

  title={Aromatase and its inhibitors: significance for breast cancer therapy.},
  author={Evan R. Simpson and Mitch Dowsett},
  journal={Recent progress in hormone research},
Endocrine adjuvant therapy for breast cancer in recent years has focussed primarily on the use of tamoxifen to inhibit the action of estrogen in the breast. The use of aromatase inhibitors has found much less favor due to poor efficacy and unsustainable side effects. Now, however, the situation is changing rapidly with the introduction of the so-called phase III inhibitors, which display high affinity and specificity towards aromatase. These compounds have been tested in a number of clinical… 

Figures and Tables from this paper

Development of Steroidal Aromatase Inhibitors as Potential Anti-breast Cancer Agents

S steroidal aromatase inhibitors, being more selective inhibitors and having certain other advantages, overruled the discovery of novel aromat enzyme inhibitors compared to the non-steroidal aromatases inhibitors which lack selectivity for CYP450 arom atase.

Aromatase and Aromatase Inhibitors in Breast Cancer Treatment

A review article aims to highlight about aromatase enzyme, its mechanism and aromat enzyme inhibitors used in the treatment of breast cancer.

Hormonal Therapy in Postmenopausal Women with Breast Cancer

The treatment of postmenopausal women with breast cancer presents a number of challenges and numerous options are now available to provide effective palliation for patients with advanced disease, including antiestrogens, pure antiestrogen, aromatase inhibitors and progestins and LHRH agonists.

Aromatase inhibitors for breast cancer: lessons from the laboratory

An alternative strategy of oestrogen deprivation in postmenopausal women with aromatase inhibitors is set to replace tamoxifen based on better efficacy and a delay in the emergence of endocrine resistance.

Novel concepts for the chemoprevention of breast cancer through aromatase inhibition.

The evidence to support the potential efficacy of AIs in the chemoprevention setting is reviewed, with a discussion of novel concepts of utilising AIs, so that they reduce breast cancer risk while minimising systemic toxicity, and the importance of accurately developing risk prediction algorithms.

New and translational perspectives of oestrogen deprivation in breast cancer

Fulvestrant in the treatment of luminal metastatic breast cancer: the balance of effectiveness and safety

Fulvestrant has a satisfactory toxicity profile, does not require supporting therapy, and is included in the clinical recommendations for monotherapy and combination therapy.

Prevention of hormone-related cancers: breast cancer.

  • B. DunnD. WickerhamL. Ford
  • Medicine, Biology
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2005
Based on promising data involving reduction of contralateral breast cancer risk in adjuvant studies, several aromatase inhibitors are being incorporated into trials evaluating their efficacy as preventive agents in women at increased risk.

The role of aromatase inhibitors as adjuvant therapy in early breast cancer

The largest adjuvant breast cancer study till date to provide data is reviewed, the ‘Arimidex’, Tamoxifen, Alone or in Combination (ATAC) trial, focusing on the current clinical status of AIs as adjuants for early-stage breast cancer in postmenopausal women.

Aromatase inhibitors in the treatment and prevention of breast cancer.

  • P. GossK. Strasser
  • Medicine, Biology
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2001
The ongoing adjuvant trials will provide important data on the long-term safety of aromatase inhibitors, which will help to determine their suitability for use as chemopreventives in healthy women at risk of developing breast cancer.

Biology of aromatase inhibitors: pharmacology/endocrinology within the breast.

  • W. Miller
  • Medicine, Biology
    Endocrine-related cancer
  • 1999
It has been shown that drugs such as letrozole profoundly inhibit in situ aromatase activity and reduce endogenous oestrogens within the breast.

The importance of local synthesis of estrogen within the breast

Intracellular aromatase and its relevance to the pharmacological efficacy of aromatase inhibitors

Comparative clinical pharmacology and pharmacokinetic interactions of aromatase inhibitors

Comparison of the systemic and intratumoral effects of tamoxifen and the aromatase inhibitor vorozole in postmenopausal patients with primary breast cancer.

The correlation with vorozole of Ki67 with volume and clinical response supports this as an intermediate marker and the nonsignificant effects on bone and lipid metabolism by the aromatase inhibitor may be important to consider for adjuvant and potential prevention strategies.

Comparison of the selective aromatase inhibitor formestane with tamoxifen as first-line hormonal therapy in postmenopausal women with advanced breast cancer.

It is concluded that formestane is an effective and well tolerated addition to the therapeutic options available for the treatment of postmenopausal women with advanced breast cancer and comparable to tamoxifen for both efficacy and tolerability.

The effects of aromatase inhibitors and antiestrogens in the nude mouse model

These aromatase inhibitors may not only benefit patients who have relapsed from tamoxifen, but may be more effective in patients as first line agents for suppressing the effects of estrogen.

1. Estrogen antagonists. Aromatase inhibitors, their pharmacology and application.

The results in animal models suggest that highly potent aromatase inhibitors may be useful for breast cancer treatment and for other oestrogen related clinical problems.